GammaCan Reports on Patient Enrollment in Phase II Clinical Trial; Company Pursues Toxicity and Efficacy Study of GCAN 101, Proprietary IVIg Therapy for Metastatic Cancers
Posted on: Tuesday, 26 July 2005, 09:00 CDT
GammaCan International (OTC BB:GCAN), a developer of immunotherapies for cancer, today announced that the Phase II clinical trial of GCAN 101 for the treatment of metastatic melanoma, prostate and/or colon cancers is underway. The Company reported that patient recruitment and treatment has commenced.
"It is our hope that the favorable results demonstrated in preclinical trials will be seen in the present trial in patients in the treatment of metatstatic cancers and may provide a viable treatment option in the future for patients at risk of recurrent cancerous tumors," stated Vered Caplan, CEO.
About GammaCan
GammaCan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that could be effective in reducing the metastatic spread of a wide range of cancers. The proposed treatment is based on IVIg, a safe relatively non-toxic human plasma based product current used to treat a variety of immune deficiencies and autoimmune diseases. Annual worldwide sales of IVIg exceed $1.5 billion U.S. dollars. For more information, visit the Company's website at www.gammacan.com.
Safe Harbor
Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.
Source: Business Wire
Related Articles
- Lifestyle Interventions In The Prevention, Treatment Of Cancer
- Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of Cancer
- Noninvasive Imaging of Cell-Mediated Therapy for Treatment of Cancer
- St. Mary Medical Center Announces a $13+ Million Investment in Five New Significant Advances in Early Diagnosis and Treatment of Cancer
- The Cancer Cure Coalition Supports the Nomination of Dr. Andrew Von Eschenbach As Commissioner of the U.S. FDA and Calls for the Approval of Advexin, a New Gene Therapy Treatment for Cancer
- Ebert Looks Forward to Return to Work
- Insight into the anti-cancer effect of exercise
- Aethlon Medical Expands Device Pipeline to Include the Treatment of Cancer
- We Should All Look Forward to a Productive New School Year
- Major Breakthrough in the Treatment of Cancers and Infectious Diseases
 |
 |
User Comments (0)
RSS Feeds